Bromodomain Inhibitors Correct Bioenergetic Deficiency Caused by Mitochondrial Disease Complex I Mutations
详细信息 查看全文
- 作者：Joeva J. Barrow1 ; 2 ; 5 ; Eduardo Balsa1 ; 2 ; 5 ; Francisco Verdeguer1 ; 2 ; Clint D.J. Tavares1 ; 2 ; Meghan S. Soustek1 ; 2 ; Louis R. Hollingsworth IV1 ; Mark Jedrychowski2 ; Rutger Vogel1 ; 2 ; 4 ; Joao A. Paulo2 ; Jan Smeitink4 ; Steve P. Gygi2 ; John Doench3 ; David E. Root3 ; Pere Puigserver1 ; 2 ; 3 ; 6 ; pere_puigserver@dfci.harvard.edu" class="auth_mail" title="E-mail the corresponding author
- 关键词：BRD4 ; bromodomain inhibitors ; mitochondria ; mitochondrial disorders ; OXPHOS ; PGC-1α
- 刊名：Molecular Cell
- 出版年：2016
- 出版时间：6 October 2016
- 年：2016
- 卷：64
- 期：1
- 页码：163-175
- 全文大小：4361 K
文摘
- •
Bromodomain inhibitors or BRD4 ablation boosts OXPHOS capacity in CI mutant cells
- •
Inhibition of BRD4 rescues CI mutant cells from galactose-induced cell death
- •
BRD4 binds to OXPHOS promoters and competes with PGC-1α binding
- •
Bromodomain inhibition rewires the metabolome in CI mutant cells to preserve ATP